LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "bispecific cell" as a keyword



Bispecific T‐cell engagers for treatment of multiple myeloma

Sign Up to like & get
recommendations! Published in 2022 at "American Journal of Hematology"

DOI: 10.1002/ajh.26628

Abstract: Bispecific T cell engagers (TCE) derive from monoclonal antibodies and concomitantly engage a target on the surface of cancer cell and CD3 on the surface of T‐cells. TCEs promote T cell activation and lysis of… read more here.

Keywords: cell engagers; cell; multiple myeloma; bispecific cell ... See more keywords

Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment

Sign Up to like & get
recommendations! Published in 2017 at "Clinical Pharmacology and Therapeutics"

DOI: 10.1002/cpt.651

Abstract: Bispecific T‐cell Engagers (BiTE®) antibody constructs enable a polyclonal T‐cell response to cell‐surface tumor‐associated antigens, bypassing the narrow specificities of T‐cell receptors and the need for antigen presentation through the major histocompatibility complex pathways. Blinatumomab,… read more here.

Keywords: bite antibody; bispecific cell; pharmacology; cell ... See more keywords
Photo from wikipedia

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies

Sign Up to like & get
recommendations! Published in 2020 at "Annals of Hematology"

DOI: 10.1007/s00277-020-04221-0

Abstract: The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is… read more here.

Keywords: bispecific cell; cell malignancies; immuno oncology; cell engager ... See more keywords

Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats

Sign Up to like & get
recommendations! Published in 2020 at "Current Medical Science"

DOI: 10.1007/s11596-020-2143-y

Abstract: Selecting an ideal molecular format from diverse structures is a major challenge in developing a bispecific antibody (BsAb). To choose an ideal format of anti-CD3 × anti-transferrin receptor (TfR) bispecific antibodies for clinical application, we… read more here.

Keywords: chain; bispecific cell; anti transferrin; cell engager ... See more keywords

Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers.

Sign Up to like & get
recommendations! Published in 2025 at "Seminars in hematology"

DOI: 10.1053/j.seminhematol.2025.08.004

Abstract: Bispecific T cell engagers (bispecific TCEs) are engineered antibodies that redirect T cells to mediate tumor cell killing by simultaneously binding to CD3 on T cells and tumor-associated antigens. As of July 2025, ten bispecific… read more here.

Keywords: family; cd3; bispecific cell; bispecific tces ... See more keywords

Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy

Sign Up to like & get
recommendations! Published in 2025 at "Proceedings of the National Academy of Sciences of the United States of America"

DOI: 10.1073/pnas.2409564122

Abstract: Significance Persistent tumor antigen exposure leads to T cell exhaustion during bispecific T cell engager (BiTE) therapy. T cell exhaustion is a condition in which T cells lose the ability to effectively kill tumors. To… read more here.

Keywords: bispecific cell; cell; drug loaded; cell exhaustion ... See more keywords

Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia

Sign Up to like & get
recommendations! Published in 2017 at "Expert Review of Hematology"

DOI: 10.1080/17474086.2017.1396890

Abstract: ABSTRACT Introduction: Immunotherapy is a promising modality of treatment of neoplastic diseases, including acute lymphoblastic leukemia (ALL). The CD19/CD3-bispecific T cell–engaging (BiTE®) monoclonal antibody blinatumomab can transiently bind cytotoxic T cells to CD19+ target B… read more here.

Keywords: bispecific cell; cell; safety; lymphoblastic leukemia ... See more keywords

Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia

Sign Up to like & get
recommendations! Published in 2018 at "Expert Review of Hematology"

DOI: 10.1080/17474086.2018.1540928

Abstract: ABSTRACT Introduction: The clinical application of immunotherapy has resulted into a significant improvement in the outcome of children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL). In this setting, the use of bispecific T-cell-engager… read more here.

Keywords: bispecific cell; cell; acute lymphoblastic; lymphoblastic leukemia ... See more keywords

EXTH-135. Intrathecally delivered T cells precomplexed with a Bispecific T-cell Engager target CNS tumors

Sign Up to like & get
recommendations! Published in 2025 at "Neuro-Oncology"

DOI: 10.1093/neuonc/noaf201.1467

Abstract: Despite recent advances, glioblastoma (GBM) and leptomeningeal disease (LMD) continue to have a dismal clinical trajectory. Immunotherapeutic strategies, particularly targeted T-cell–based therapeutics, offer promising new approaches. We investigated a novel targeted T-cell strategy where naïve… read more here.

Keywords: pbte; cell engager; bispecific cell; cell ... See more keywords

ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)

Sign Up to like & get
recommendations! Published in 2019 at "Neuro-Oncology"

DOI: 10.1093/neuonc/noz219.1195

Abstract: The class III variant of the epidermal growth factor receptor (EGFRvIII) represents the most common EGFR mutation in GBM. AMG 596 is a bispecific T cell engager (BiTE®) molecule designed to engage a patient’s own… read more here.

Keywords: bispecific cell; gbm; analysis; treatment ... See more keywords

Ex silico engineering of cystine-dense peptides yielding a potent bispecific T cell engager

Sign Up to like & get
recommendations! Published in 2022 at "Science Translational Medicine"

DOI: 10.1126/scitranslmed.abn0402

Abstract: Cystine-dense peptides (CDPs) are a miniprotein class that can drug difficult targets with high affinity and low immunogenicity. Tools for their design, however, are not as developed as those for small-molecule and antibody drugs. CDPs… read more here.

Keywords: cell engager; cdp; dense; cystine dense ... See more keywords